Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP PNET 5 MB biomarker-stratified medulloblastoma trial
NL-OMON55597Phase 3Recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, cisplatin, lomustine, vincristine, cyclophosphamide and 3 more in medulloblastoma and medulloblastoma WNT activated (WNT-MB) (6 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: 3-year event-free survival and event-free survival. Started Nov 2020; status: recruiting.
02
Drugs
carboplatincisplatinlomustinevincristinecyclophosphamide
03
Conditions
medulloblastomamedulloblastoma WNT activated (WNT-MB)
Beyond the preview
Go deeper on NL-OMON55597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55597.